Cargando…
Medications To Treat Alcoholism
Advances in neurobiology support the development of medications to treat alcoholism by modifying the activity of specific chemical messengers (i.e., neurotransmitters) in the brain. Among the most promising new medications is acamprosate, which appears to decrease the intensity of craving after a pe...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Institute on Alcohol Abuse and Alcoholism
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760424/ https://www.ncbi.nlm.nih.gov/pubmed/10890803 |
_version_ | 1783453859649159168 |
---|---|
author | Johnson, Bankole A. Ait-Daoud, Nassima |
author_facet | Johnson, Bankole A. Ait-Daoud, Nassima |
author_sort | Johnson, Bankole A. |
collection | PubMed |
description | Advances in neurobiology support the development of medications to treat alcoholism by modifying the activity of specific chemical messengers (i.e., neurotransmitters) in the brain. Among the most promising new medications is acamprosate, which appears to decrease the intensity of craving after a person has stopped drinking. Naltrexone (ReVia™) has been shown to decrease alcohol consumption, although its practical effectiveness may be compromised by poor patient compliance and other factors. Ondansetron shows promise for decreasing drinking and increasing abstinence rates among early onset alcoholics, who respond poorly to psychosocial treatment alone. Researchers are investigating whether the use of specific medications in combination can further enhance their effectiveness. Additional research is needed to determine how medications interact with different psychosocial factors and treatments. |
format | Online Article Text |
id | pubmed-6760424 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1999 |
publisher | National Institute on Alcohol Abuse and Alcoholism |
record_format | MEDLINE/PubMed |
spelling | pubmed-67604242019-10-02 Medications To Treat Alcoholism Johnson, Bankole A. Ait-Daoud, Nassima Alcohol Res Health Articles Advances in neurobiology support the development of medications to treat alcoholism by modifying the activity of specific chemical messengers (i.e., neurotransmitters) in the brain. Among the most promising new medications is acamprosate, which appears to decrease the intensity of craving after a person has stopped drinking. Naltrexone (ReVia™) has been shown to decrease alcohol consumption, although its practical effectiveness may be compromised by poor patient compliance and other factors. Ondansetron shows promise for decreasing drinking and increasing abstinence rates among early onset alcoholics, who respond poorly to psychosocial treatment alone. Researchers are investigating whether the use of specific medications in combination can further enhance their effectiveness. Additional research is needed to determine how medications interact with different psychosocial factors and treatments. National Institute on Alcohol Abuse and Alcoholism 1999 /pmc/articles/PMC6760424/ /pubmed/10890803 Text en http://creativecommons.org/publicdomain/mark/1.0/ Unless otherwise noted in the text, all material appearing in this journal is in the public domain and may be reproduced without permission. Citation of the source is appreciated. |
spellingShingle | Articles Johnson, Bankole A. Ait-Daoud, Nassima Medications To Treat Alcoholism |
title | Medications To Treat Alcoholism |
title_full | Medications To Treat Alcoholism |
title_fullStr | Medications To Treat Alcoholism |
title_full_unstemmed | Medications To Treat Alcoholism |
title_short | Medications To Treat Alcoholism |
title_sort | medications to treat alcoholism |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760424/ https://www.ncbi.nlm.nih.gov/pubmed/10890803 |
work_keys_str_mv | AT johnsonbankolea medicationstotreatalcoholism AT aitdaoudnassima medicationstotreatalcoholism |